[Bio USA] Samsung Biologics steps up CDMO tech race

▤ Summary

Samsung Biologics is expanding its CDMO technology strategy by investing in proprietary platforms, next-generation modalities, and internal R&D. The company highlighted cell-line platforms such as S-CHOice and S-AfuCHO that aim to cut development time and lower manufacturing costs for clients. It is also advancing antibody, ADC, AAV, RNA, and mRNA technologies and plans to monetize some of them through licensing agreements. These moves strengthen its position in life sciences services and create more options for partners that need development, manufacturing, or platform access.

▦ Linked Companies